Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer

Learn more about the evolving role of CDK4/6 inhibitors to treat patients with HR-positive/HER2-negative breast cancer through a certified on-demand webcast, downloadable self-teaching slideset, and podcast.

Share

Program Content

Activities

CDK4_6 Inhibitors in HR+, HER2-Negative Breast Cancer
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2024

Expires: May 29, 2025

Activities

HR Positive HER2 Negative Breast Cancer at ASCO 2024
Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2024

Expires: June 16, 2025

Faculty

cover img faculity

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

cover img faculity

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation